Urine Protein to Creatinine Ratio for the Assessment of Bevacizumab-Associated Proteinuria in Patients with Gynecologic Cancers: A Diagnostic and Quality Improvement Study

Proteinuria is a common adverse event arising from treatment with bevacizumab, requiring diagnostic testing via 24-h urine collection. However, this method is cumbersome. We assessed urine screenings in gynecologic cancer patients from February 2021 to May 2022. Along with a simple urine dipstick (U...

Полное описание

Библиографические подробности

Главные авторы:	Kuan-Ju Huang, Wen-Chun Chang, Chi-Hau Chen, Wei-Chen Lin, William Wei-Lin Pan, Hao-I. Hsieh, Yu-Hsiung Hsieh, Lin-Hung Wei, Bor-Ching Sheu
Формат:	Artigo
Язык:	Inglês
Опубликовано:	MDPI AG 2024-08-01
Серии:	Diagnostics
Предметы:	urine protein to creatinine ratio bevacizumab angiogenesis inhibitors antineoplastic agents proteinuria albuminuria
Online-ссылка:	https://www.mdpi.com/2075-4418/14/17/1852
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!